eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
1/2018
vol. 4
 
Share:
Share:
more
 
 
abstract:
Review paper

LABA/LAMA in the treatment of chronic obstructive pulmonary disease based on the latest research results

Małgorzata Farnik

Online publish date: 2018/03/12
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Chronic obstructive pulmonary disease (COPD) is characterised by progressive irreversible airflow limitation and exercise intolerance. Bronchodilators are the first-choice treatment in COPD. According to the guidelines in stable CO PD treatment, long-acting bronchodilators – long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) – are recommended. It was found that LAMA and LABA improve lung function, and decrease dyspnoea and exacerbation risk. Recently published data compare different treatment options including bronchodilator monotherapy and bronchodilator combination (LABA/LAMA) as well as some different options of combination treatment. Combination bronchodilator therapy compared to monotherapy or LABA/GCS was found to be more effective in the context of exacerbations. Triple therapy (bronchodilators plus GCS) should be indicated in patients with dyspnoea and exacerbations – at least in the past two years.
keywords:

chronic obstructive pulmonary disease (COPD), bronchodilator, long-acting muscarinic antagonists, long-acting beta-agonists, combination therapy

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe